Inflammations has been increasingly identified as a major risk factor across many disease areas particularly in Cardiovascular, immunological and auto-immune diseases. We have extensive experience in Phase 2 to Phase 3 clinical trials including major outcome studies involving anti-inflammatory drugs. Our deep understanding of key inflammatory biomarkers and safety parameters helps in efficient clinical trials designs.
We bring together experts with extensive experience in immunological studies to the table. in conjunction with our other core therapeutic specialty divisions, we can provide you with optimal strategic, scientific, and operational solutions.